RxDoctor Payments Data

Carlos Vela-Sandoval, MD

Internal Medicine · Springdale, ARNPI 1609033265

Payments from drug & device makers

$255in general payments, 2019–2025

Across 11 payments — averaging $23.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$73
  • Amgen$47
  • Novo Nordisk$38
  • Otsuka America Pharmaceutical, Inc.$25
  • Astellas Pharma US Inc$22
  • AstraZeneca$20
  • plus $30 from 2 others

What the payments were for

  • Food & beverage$255100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$255 in reported general payments places this provider in the 50th percentile of 614 internal medicine providers in Arkansas.

See all internal medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$79,352
Medicare patients
197
Services billed
1,367

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin131$144,643
RinvoqUpadacitinib16$140,995
OzempicSemaglutide91$123,019
EliquisApixaban114$121,062
XareltoRivaroxaban98$81,087
JanuviaSitagliptin Phosphate77$79,082
Trelegy ElliptaFluticasone/Umeclidin/Vilanter72$69,583
MounjaroTirzepatide61$68,658
FarxigaDapagliflozin Propanediol48$61,593
TrulicityDulaglutide28$46,010
Dupixent PenDupilumab11$40,951
TradjentaLinagliptin30$39,181
Stiolto RespimatTiotropium Br/Olodaterol Hcl39$30,324
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog30$29,898
MyrbetriqMirabegron28$22,743

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$38$123,01991 claims
AstraZenecaFarxiga$20$61,59348 claims
Astellas Pharma US IncMyrbetriq$22$22,74328 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 614 internal medicine providers in Arkansas.

Other internal medicine in Springdale

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →